Tags

Type your tag names separated by a space and hit enter

The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines.
Headache 2012; 52(6):930-45H

Abstract

BACKGROUND

Updated guidelines for the preventive treatment of episodic migraine have been issued by the American Headache Society (AHS) and the American Academy of Neurology (AAN). We summarize key 2012 guideline recommendations and changes from previous guidelines. We review the characteristics, methods, consistency, and quality of the AHS/AAN guidelines in comparison with recently issued guidelines from other specialty societies.

METHODS

To accomplish this, we reviewed the AHS/AAN guidelines and identified comparable recent guidelines through a systematic MEDLINE search. We extracted key data, and summarized and compared the key recommendations and assessed quality using the Appraisal of Guidelines Research and Evaluation-II (AGREE-II) tool. We identified 2 additional recent guidelines for migraine prevention from the Canadian Headache Society and the European Federation of Neurological Societies. All of the guidelines used structured methods to locate evidence and linked recommendations with assessment of the evidence, but they varied in the methods used to derive recommendations from that evidence.

RESULTS

Overall, the 3 guidelines were consistent in their recommendations of treatments for first-line use. All rated topiramate, divalproex/sodium valproate, propranolol, and metoprolol as having the highest level of evidence. In contrast, recommendations diverged substantially for gabapentin and feverfew. The overall quality of the guidelines ranged from 2 to 6 out of 7 on the AGREE-II tool.

CONCLUSION

The AHS/AAN and Canadian guidelines are recommended for use on the basis of the AGREE-II quality assessment. Recommendations for the future development of clinical practice guidelines in migraine are provided. In particular, efforts should be made to ensure that guidelines are regularly updated and that guideline developers strive to locate and incorporate unpublished clinical trial evidence.

Authors+Show Affiliations

Graham Headache Center and the Department of Neurology, Division of Headache and Pain, Brigham and Women's and Faulkner Hospitals, Boston, MA, USA. eloder@partners.orgNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

22671714

Citation

Loder, Elizabeth, et al. "The 2012 AHS/AAN Guidelines for Prevention of Episodic Migraine: a Summary and Comparison With Other Recent Clinical Practice Guidelines." Headache, vol. 52, no. 6, 2012, pp. 930-45.
Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012;52(6):930-45.
Loder, E., Burch, R., & Rizzoli, P. (2012). The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache, 52(6), pp. 930-45. doi:10.1111/j.1526-4610.2012.02185.x.
Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN Guidelines for Prevention of Episodic Migraine: a Summary and Comparison With Other Recent Clinical Practice Guidelines. Headache. 2012;52(6):930-45. PubMed PMID: 22671714.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. AU - Loder,Elizabeth, AU - Burch,Rebecca, AU - Rizzoli,Paul, PY - 2012/6/8/entrez PY - 2012/6/8/pubmed PY - 2012/10/13/medline SP - 930 EP - 45 JF - Headache JO - Headache VL - 52 IS - 6 N2 - BACKGROUND: Updated guidelines for the preventive treatment of episodic migraine have been issued by the American Headache Society (AHS) and the American Academy of Neurology (AAN). We summarize key 2012 guideline recommendations and changes from previous guidelines. We review the characteristics, methods, consistency, and quality of the AHS/AAN guidelines in comparison with recently issued guidelines from other specialty societies. METHODS: To accomplish this, we reviewed the AHS/AAN guidelines and identified comparable recent guidelines through a systematic MEDLINE search. We extracted key data, and summarized and compared the key recommendations and assessed quality using the Appraisal of Guidelines Research and Evaluation-II (AGREE-II) tool. We identified 2 additional recent guidelines for migraine prevention from the Canadian Headache Society and the European Federation of Neurological Societies. All of the guidelines used structured methods to locate evidence and linked recommendations with assessment of the evidence, but they varied in the methods used to derive recommendations from that evidence. RESULTS: Overall, the 3 guidelines were consistent in their recommendations of treatments for first-line use. All rated topiramate, divalproex/sodium valproate, propranolol, and metoprolol as having the highest level of evidence. In contrast, recommendations diverged substantially for gabapentin and feverfew. The overall quality of the guidelines ranged from 2 to 6 out of 7 on the AGREE-II tool. CONCLUSION: The AHS/AAN and Canadian guidelines are recommended for use on the basis of the AGREE-II quality assessment. Recommendations for the future development of clinical practice guidelines in migraine are provided. In particular, efforts should be made to ensure that guidelines are regularly updated and that guideline developers strive to locate and incorporate unpublished clinical trial evidence. SN - 1526-4610 UR - https://www.unboundmedicine.com/medline/citation/22671714/The_2012_AHS/AAN_guidelines_for_prevention_of_episodic_migraine:_a_summary_and_comparison_with_other_recent_clinical_practice_guidelines_ L2 - https://doi.org/10.1111/j.1526-4610.2012.02185.x DB - PRIME DP - Unbound Medicine ER -